Mar 16–19, 2025 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Katy Rezvani, Nathan Singh, and Stephan Mielke

-
Scientific Organizers: Katy Rezvani, Nathan Singh, and Stephan Mielke
Katy Rezvani
Nathan Singh
Stephan Mielke
***Meeting program subject to change.
Available Formats: = In Person = On DemandMerchandise Options
Registration Options
Sunday, March 16, 2025
Fundraising
Booking Function
Monday, March 17, 2025
Session Chair
Session Chair
Cell Therapies: Current State-of the Art
Dissecting T Cell Recognition of Cancer
Genomic Regulation of CAR-Driven T Cell Dysfunction
Rational Combination of Therapies to Stimulate the APC Compartment
Metabolic Interventions to Enhance Adoptive Cellular Therapies
AI/ML-Driven Discovery of a Novel Proteoglycan for Precision Targeting of Solid Tumors by T Cell Engagers
Session Chair
In Vivo Spatial Pooled Screening Identifies CAR T Constructs with Superior Anti-Solid Tumor Efficacy and Safety
Generation of MHC-Independent T Cell Receptors Using Rational Protein Engineering
Human T Cell Receptors Equipped with Inducible Co-Stimulator Mediate Durable Anti-Tumor Activity
Single-Cell Profiling Reveals Functional Dynamics Of Adapter CAR-T Cells Targeting CD33+ Acute Myeloid Leukemia
Striking a Balance: Human CAR19+ CD8-Itreg for Prevention of GVHD And Enhanced Anti-Leukemic Efficacy Without Systemic Toxicity
Continuous Expression of TOX Safeguards Exhausted CD8 T Cell Epigenetic Fate
Asymmetric Epigenetic and Metabolic Remodeling of Engineered CD4 T Cells Drives Divergent Cell Fate
Generation of iPSC-Derived CD4+ and CD8+ CD19 CAR T Cells with Robust in Vivo Tumor Control and Persistence
Myeloid Cell States as Regulators Of CAR-T Cell Function
Advancing Locoregional CAR T Cell Therapy for Pediatric CNS Tumors
Driving Complex CAR-T into the Clinic – What, Why, and How
Cytokine Armored GPC3-CAR T Cells for Patients with Solid Tumors
Short Talk: In Vivo CRISPRa Screens Uncover Positive and Negative Regulators of T Cell Accumulation in the Immunocompetent Tumor Microenvironment
Short Talk: Balancing Efficacy and Safety: Overcoming On-Target Off-Tumor Toxicity of Claudin18.2-Directed CAR-T Cells in Preclinical Models
Tuesday, March 18, 2025
CAR T Cells: A European Perspective
Improving Access to Cell Therapies
Professor and Director
Associate Professor
Chief Scientific Officer
CSO Partner
Deputy Editor
CAR T Cells for B-cell mediated Autoimmune Disease
Clinical and Translational Development of Engineered T Cell Therapy for Autoimmune Disease
CAR Tregs
Short Talk: Alloantigen-Specific CAR Tregs Mediate Islet Protection By Suppressing Islet Autoantigen-Specific T Cells
Wednesday, March 19, 2025
Session Chair
Remote Presentation: CAR-M: Engineering Myeloid Cells ex vivo and in vivo for Cancer Immunotherapy
Engineering NK Cells for Cancer Immunotherapy
Use of iPSC for Programmed Cellular Immunotherapies
Mastering Diversity of gdT Cells and the Receptors for Cancer Immune Therapies
Short Talk: CAR Engineered Dcs Respond to Tumor in a Signaling Distinct Manner
Short Talk: Elucidating Molecular Mechanisms of NK Cell Function from the Studies of NK Cell Desensitization and Exhaustion for Improved Anti-Cancer Therapies
Session Chair
Hybrid-R: Overcoming Limitations in T Cell Therapy With A Single Synthetic Receptor
Innate Immune Receptor-Based Cars For In Vivo Programming of Myeloid Cells to Combat Solid Tumors
Amyloid Plaque Targeting Chimeric Antigen Receptor Macrophages for Alzheimer’s Disease Therapy
Exploring the Potential Of CAR-Engineered Hscs for Treating B-Cell Acute Lymphoblastic Leukemia
Differentiation of Human CD4+ T Cells from Pluripotent Stem Cells
Enhancing CAR-NK Potency and Persistence with Myd88/CD40 Costimulation
Remote Presentation: Engineering of Myeloid Cells
Nature Inspired Design
CRISPR-Based T Cell Editing to Enhance Cell Therapy
Thursday, March 20, 2025
Subscribe for Updates